HARVONI Drug Patent Profile

« Back to Dashboard

Which patents cover Harvoni, and what generic alternatives are available?

Harvoni is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are seventeen patents protecting this drug.

The generic ingredient in HARVONI is ledipasvir; sofosbuvir. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ledipasvir; sofosbuvir profile page.

DrugPatentWatch^® Generic Entry Outlook for Harvoni

Harvoni was eligible for patent challenges on October 10, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 12, 2030. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for HARVONI

US Patents:	17
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	36
Patent Applications:	100
Drug Prices:	Drug price information for HARVONI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for HARVONI
What excipients (inactive ingredients) are in HARVONI?	HARVONI excipients list
DailyMed Link:	HARVONI at DailyMed

See drug prices for HARVONI

See drug sales revenues for HARVONI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for HARVONI

Constraining patent/regulatory exclusivity:

8,088,368*PED

NDA:

212477

Dosage:

PELLETS;ORAL

Constraining patent/regulatory exclusivity:

8,088,368*PED

NDA:

205834

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for HARVONI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mansoura University	Phase 3
Cairo University	Phase 2/Phase 3
University of Maryland, College Park	Early Phase 1

See all HARVONI clinical trials

Pharmacology for HARVONI

Drug Class	Hepatitis C Virus NS5A Inhibitor Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors P-Glycoprotein Inhibitors RNA Replicase Inhibitors

US Patents and Regulatory Information for HARVONI

HARVONI is protected by seventeen US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,088,368.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-001	Oct 10, 2014		RX	Yes	Yes	9,284,342*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No	8,334,270*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477-002	Aug 28, 2019		RX	Yes	Yes	9,393,256*PED				Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No	8,735,372*PED				Y

International Patents for HARVONI

When does loss-of-exclusivity occur for HARVONI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

Montenegro

Netherlands

New Zealand

Norway

Peru

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering HARVONI around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	095131
Argentina	130558
Australia	2014202687
Australia	2015202842

Supplementary Protection Certificates for HARVONI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203462	214 5029-2014	Slovakia		PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117
2430014	CA 2016 00006	Denmark		PRODUCT NAME: LEDISPAVIR; REG. NO/DATE: EU/1/14/958/001-002 20141118
2203462	C300704	Netherlands		PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
2203462	PA2014040	Lithuania		PRODUCT NAME: SOFOSBUVIRUM; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116

Harvoni Market Dynamics, Financial Trajectory, Patent Exclusivity, and Generic Entry Risk

Last updated: October 6, 2026

Harvoni, Gilead Sciences’ ledipasvir/sofosbuvir fixed-dose combination, transformed the hepatitis C market after its 2014 launch. U.S. sales peaked at approximately $13.9 billion in 2015 before falling below $1 billion by 2020 as the treated patient pool contracted, competing direct-acting antivirals gained share, and pricing pressure increased. Harvoni remains commercially relevant through residual demand, international markets, and authorized-generic economics, but its growth phase has ended.

How did Harvoni sales change after launch?

Harvoni generated exceptional early revenue because it offered a once-daily, interferon-free treatment with high cure rates for genotype 1 hepatitis C. The initial commercial opportunity included millions of diagnosed and undiagnosed patients, but the addressable population declined rapidly after the first treatment wave.

Fiscal year	Harvoni product sales	Year-over-year trend
2014	Approximately $2.1 billion	Partial launch year
2015	Approximately $13.9 billion	Peak
2016	Approximately $9.1 billion	Down sharply
2017	Approximately $4.4 billion	Continued erosion
2018	Approximately $2.1 billion	Continued erosion
2019	Approximately $1.1 billion	Continued erosion
2020	Approximately $0.8 billion	Generic and competitive pressure
2021	Approximately $0.6 billion	Mature product
2022	Approximately $0.5 billion	Mature product
2023	Approximately $0.4 billion	Residual sales

Source: Gilead Sciences annual reports and Form 10-K filings.[1-6]

From the 2015 peak through 2023, Harvoni revenue declined by roughly 97%. The decline was structural rather than cyclical. The principal drivers were:

• Treatment of a large backlog of diagnosed patients during the first two years.
• Increasing use of pan-genotypic alternatives such as Epclusa and Mavyret.
• Reduced prevalence among commercially insured patients.
• Payer restrictions and mandatory discounts.
• Expansion of generic or authorized-generic hepatitis C products.
• Lower treatment duration and increased competition for untreated patients.

What drove Harvoni’s initial market success?

Harvoni combined ledipasvir, an NS5A inhibitor, with sofosbuvir, an NS5B nucleotide polymerase inhibitor. The regimen was administered once daily and generally used for eight or 12 weeks depending on treatment history, viral load, and cirrhosis status.

The product’s commercial advantages included:

1. High sustained virologic response rates.
2. Oral dosing without interferon.
3. Short treatment duration.
4. Strong physician familiarity with sofosbuvir.
5. A broad initial genotype 1 indication, the largest U.S. hepatitis C segment at launch.

The launch price was approximately $94,500 for a standard 12-week course in the United States. Gilead defended the price by linking it to the clinical and economic value of curing hepatitis C, including reduced progression to cirrhosis, liver cancer, and transplantation. State Medicaid programs, commercial insurers, and public payers responded with utilization controls, prior authorization, and negotiated rebates.

Harvoni’s revenue peak reflected both price and volume. Its later decline reflected the loss of both variables.

How does Harvoni compare with competing hepatitis C drugs?

Harvoni initially held a strong position against AbbVie’s Viekira Pak. The competitive landscape changed after the launch of pan-genotypic regimens.

Product	Active ingredients	Company	Commercial position
Harvoni	Ledipasvir/sofosbuvir	Gilead Sciences	Early genotype 1 leader; mature product
Sovaldi	Sofosbuvir	Gilead Sciences	Foundational sofosbuvir product
Epclusa	Sofosbuvir/velpatasvir	Gilead Sciences	Pan-genotypic successor
Mavyret	Glecaprevir/pibrentasvir	AbbVie	Short-course, pan-genotypic competitor
Vosevi	Sofosbuvir/velpatasvir/voxilaprevir	Gilead Sciences	Retreatment and resistance setting
Viekira Pak	Ombitasvir/paritaprevir/ritonavir/dasabuvir	AbbVie	Early competitor, later displaced

Epclusa and Mavyret reduced Harvoni’s strategic importance because they covered all major hepatitis C genotypes and were positioned for broader first-line use. Mavyret also benefited from an eight-week treatment option for many patients and aggressive payer contracting.

Harvoni retained a role in patients with genotype-specific treatment needs, physician familiarity, and established reimbursement pathways. It no longer represented Gilead’s primary hepatitis C growth asset.

What is Harvoni’s FDA regulatory status?

The FDA approved Harvoni on October 10, 2014, for chronic hepatitis C genotype 1 infection in adults.[7] Subsequent label expansions extended use to additional genotypes and pediatric patients.

FDA milestone	Date or status
Original U.S. approval	October 10, 2014
Initial indication	Chronic HCV genotype 1 in adults
Expanded genotype coverage	Genotypes 4, 5 and 6 under later labeling
Pediatric approval	Patients aged 3 years and older
Dosage form	Oral fixed-dose tablet; granules also authorized for pediatric use
Regulatory category	Small-molecule prescription drug
Biosimilar pathway	Not applicable

Harvoni is not a biologic. Biosimilar competition does not apply. Competitive entry occurs through abbreviated new drug applications, authorized generics, licensing arrangements, or full generic development under the Hatch-Waxman framework.

What patents protect Harvoni?

Harvoni’s protection has relied on patents covering sofosbuvir, ledipasvir, the active combination, and related pharmaceutical compositions. The commercial importance of individual patents has changed as core composition patents expired or approached expiration.

Patent category	Protected subject matter	Commercial relevance
Sofosbuvir composition patents	Nucleotide analog and related compounds	Core active-ingredient protection
Ledipasvir composition patents	NS5A inhibitor compounds	Harvoni-specific component protection
Combination patents	Ledipasvir with sofosbuvir	Fixed-dose product protection
Formulation patents	Tablets, granules, excipients and dosage forms	Product and pediatric formulation barriers
Method-of-use patents	Treatment of HCV patients and specific genotypes	Potential use-code and litigation leverage

Public patent records identify U.S. patents associated with sofosbuvir and ledipasvir, including U.S. Patent Nos. 8,735,372 and 9,463,205. Expiration dates depend on patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, and the specific Orange Book listing.[8]

A single “Harvoni expiration date” is therefore incomplete. The relevant date depends on whether a challenger targets the active ingredient, combination, formulation, or method of use.

What is the Orange Book status of Harvoni?

Harvoni is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The Orange Book identifies patents and exclusivity information submitted by the reference sponsor.

The principal commercial questions are:

• Which patents remain listed for the specific dosage form?
• Whether the patent protects the product or only a method of use.
• Whether a generic applicant can carve out a patented indication.
• Whether a Paragraph IV certification has been filed.
• Whether settlement terms delay commercial launch.
• Whether the reference sponsor has authorized a generic product.

Orange Book listing does not guarantee that a patent will survive litigation. It establishes a statutory pathway for notice, certification, and potential litigation under Hatch-Waxman.

When does Harvoni lose exclusivity?

Harvoni’s practical exclusivity loss occurred in stages rather than on one date.

Market exclusivity

The original FDA new chemical entity exclusivity period expired in 2019, five years after approval. That period prevented approval of certain abbreviated applications but did not eliminate patent-based barriers.

Patent exclusivity

Patent protection extended beyond regulatory exclusivity. Core compound and combination patents have expiration dates that vary by jurisdiction and patent family. In the United States, patent-related barriers for sofosbuvir- and ledipasvir-based products have extended into the late 2020s and, for certain claims, beyond that period.

Commercial exclusivity

Commercial exclusivity weakened before the last patent expiration because Gilead entered licensing and settlement arrangements allowing selected generic suppliers to operate in defined markets or after agreed dates. Authorized-generic availability also reduced the practical value of later patent protection.

The result is a gap between formal patent exclusivity and effective branded pricing power.

Which companies challenged Harvoni patents?

Generic-drug companies and hepatitis C manufacturers challenged or negotiated around Gilead’s patent estate in the United States and international markets. Participants in the broader sofosbuvir and ledipasvir competitive field have included:

• Teva Pharmaceuticals.
• Mylan, now part of Viatris.
• Cipla.
• Hetero.
• Natco Pharma.
• Aurobindo Pharma.
• Apotex.
• Other regional manufacturers operating under licensing arrangements.

The precise challenger set differs by patent, dosage form, country, and litigation docket. Some companies pursued patent challenges, while others entered settlement or license arrangements without creating an immediate at-risk launch.

What generic launch risks exist for Harvoni?

Harvoni has three principal generic-entry scenarios.

Authorized-generic substitution

Gilead created Asegua Therapeutics to commercialize lower-priced versions of certain hepatitis C medicines, including authorized generic versions of Harvoni and Epclusa. The authorized-generic strategy allowed Gilead to capture value from price-sensitive segments while limiting the commercial impact of independent generic entrants.[9]

Licensed generic entry

Gilead entered voluntary licensing arrangements with generic manufacturers for selected low- and middle-income countries. Those agreements expanded access while preserving a controlled commercial structure outside major high-income markets.[10]

Independent Paragraph IV launch

A successful Paragraph IV challenge could permit an independent generic launch before the expiry of all listed patents. The main risks would be:

• At-risk launch litigation.
• 180-day first-filer dynamics.
• Indication carve-outs.
• Patent settlement restrictions.
• Product liability and manufacturing scale-up.
• Rapid price compression after multiple entrants.

The largest financial risk is not loss of all Harvoni revenue at once. It is accelerated erosion of remaining branded revenue and reduced ability to maintain premium pricing in government and commercial channels.

What patent litigation affects Harvoni?

The most important litigation has involved the sofosbuvir patent estate rather than only the finished Harvoni product. Gilead has faced patent disputes with companies and research institutions over the composition and development of sofosbuvir. Patent disputes have included challenges to validity, inventorship, ownership, and infringement.

The legal exposure has included:

• Paragraph IV litigation against generic applicants.
• Disputes over sofosbuvir compound patents.
• Licensing negotiations with generic suppliers.
• Royalty and ownership claims involving research institutions.
• Patent enforcement in foreign jurisdictions.

Litigation outcomes have had a greater effect on launch timing and royalty economics than on the long-term clinical position of Harvoni.

How strong is Harvoni’s patent estate?

Harvoni’s patent estate was strongest during the first five years after launch. Its strength has declined for commercial purposes because:

1. The earliest and most valuable patents have aged.
2. Generic manufacturers have developed manufacturing expertise.
3. Alternative regimens reduce the value of product-specific claims.
4. Payers are less willing to protect premium pricing.
5. Authorized-generic strategies have normalized lower prices.

The estate remains meaningful where combination, formulation, pediatric, or method-of-use claims are enforceable. It is weaker as a basis for maintaining branded pricing across the entire hepatitis C market.

What licensing deals affect Harvoni’s economics?

Gilead’s hepatitis C licensing strategy has had two tracks.

The first track covers voluntary licenses for developing markets. Licensees can manufacture and distribute specified products in defined countries, often subject to quality, geographic, and commercial terms.

The second track covers U.S. and developed-market generic or authorized-generic arrangements. These agreements can specify launch dates, royalties, product scope, and restrictions on litigation or commercialization.

Licensing expands patient access and limits uncontrolled patent disputes. It also converts a portion of future competitive erosion into managed revenue, royalty income, or supply-chain control.

What is Harvoni’s geographic market exposure?

Harvoni’s U.S. market generated the largest early revenue contribution because U.S. treatment prices were substantially higher than prices in Europe, Asia, and developing markets. International markets have lower revenue per patient but a longer tail because diagnosis and treatment penetration developed more gradually.

The commercial profile differs by region:

Region	Market characteristics
United States	High historical price, rapid initial treatment, strong payer pressure
Europe	Centralized or national reimbursement, lower net prices
Japan	Significant HCV treatment market with regulatory and reimbursement controls
Developing markets	Lower prices, voluntary licensing, public-health procurement
Emerging markets	Uneven diagnosis, growing generic access, price-sensitive demand

International generic licensing has reduced the risk of abrupt patent disputes but has also limited branded-volume expansion.

What manufacturing and intellectual-property barriers remain?

Harvoni is a chemically synthesized small molecule, so it does not have the cell-line, comparability, or cold-chain barriers associated with biologics. Manufacturing barriers are still material:

• Control of stereochemistry and impurity profiles.
• High-purity active pharmaceutical ingredient production.
• Reliable synthesis of sofosbuvir intermediates.
• Tablet manufacturing and stability.
• Regulatory validation across multiple jurisdictions.
• Supply-chain control for high-volume public-health programs.

These barriers favor experienced generic manufacturers but do not prevent competition. Once a supplier validates the process and secures regulatory approval, production costs can fall substantially.

What is Harvoni’s revenue exposure for Gilead?

Harvoni is no longer a material driver of Gilead’s consolidated growth. Its revenue contribution has fallen from roughly 40% of Gilead’s annual product sales at the 2015 peak to a low-single-digit share in recent years.

Gilead’s financial exposure has shifted toward:

• Biktarvy and other HIV products.
• Long-acting HIV therapies.
• Oncology products, including Trodelvy.
• Cell therapy products, including Yescarta.
• Veklury and other COVID-related revenue.
• New pipeline and business-development assets.

Harvoni remains relevant to the hepatitis C franchise, but its financial trajectory is now a declining annuity rather than a growth platform.

How does Harvoni compare with Epclusa and Mavyret?

Factor	Harvoni	Epclusa	Mavyret
Company	Gilead	Gilead	AbbVie
Core positioning	Genotype-focused legacy regimen	Pan-genotypic Gilead successor	Pan-genotypic competitor
Launch timing	2014	2016	2017
Current commercial stage	Mature and declining	Mature but strategically stronger	Mature, competitive
Biosimilar risk	None	None	None
Generic risk	High	Increasing	Increasing
Main advantage	Established clinical use and brand recognition	Broad genotype coverage	Short-course treatment and pricing

Epclusa has a stronger long-term strategic position within Gilead’s hepatitis C portfolio because it is pan-genotypic. Mavyret exerts the greatest competitive pressure through broad coverage and payer-oriented pricing.

Key Takeaways

• Harvoni sales peaked at approximately $13.9 billion in 2015.
• Revenue declined by roughly 97% from 2015 through 2023.
• The decline reflects market saturation, competition, payer restrictions, and generic access.
• Harvoni is a small molecule, so biosimilar competition does not apply.
• FDA regulatory exclusivity expired before the full patent estate ceased to matter.
• Orange Book protection depends on specific patents, dosage forms, and use claims.
• Authorized-generic and licensed-generic strategies have reduced uncontrolled launch risk.
• Epclusa and Mavyret displaced Harvoni as broad first-line hepatitis C options.
• Harvoni now has residual revenue value but limited strategic growth value for Gilead.
• The principal remaining risks are further price erosion, generic substitution, and declining treatment demand.

FAQs

What was Harvoni’s highest annual revenue?

Harvoni generated approximately $13.9 billion in product sales in 2015, its first full year on the market.

Is Harvoni still prescribed?

Yes. Harvoni remains available and may be prescribed for selected patients with chronic hepatitis C, although pan-genotypic therapies are more commonly used for broad first-line treatment.

Is there a generic version of Harvoni?

Authorized-generic versions have been commercialized through Gilead-related arrangements, and generic access exists in multiple international markets through licensing programs. Availability varies by country.

Does Harvoni have biosimilar competition?

No. Harvoni is a chemically synthesized small-molecule drug. The relevant competitors are generic and authorized-generic products.

Will Harvoni revenue continue declining?

The underlying trend is downward. Residual revenue can persist through established prescriber use, international demand, payer contracts, and licensed distribution, but no major return to peak-level sales is expected.

References

1. Gilead Sciences, Inc. (2015). Annual report for the fiscal year ended December 31, 2015.

2. Gilead Sciences, Inc. (2017). Annual report for the fiscal year ended December 31, 2017.

3. Gilead Sciences, Inc. (2019). Annual report for the fiscal year ended December 31, 2019.

4. Gilead Sciences, Inc. (2020). Annual report for the fiscal year ended December 31, 2020.

5. Gilead Sciences, Inc. (2022). Annual report for the fiscal year ended December 31, 2022.

6. Gilead Sciences, Inc. (2023). Annual report for the fiscal year ended December 31, 2023.

7. U.S. Food and Drug Administration. (2014). FDA approves first combination pill to treat hepatitis C.

8. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Harvoni patent and exclusivity information.

9. Gilead Sciences, Inc. (2019). Gilead announces authorized generic hepatitis C medicines in the United States.

10. Gilead Sciences, Inc. (2024). Hepatitis C voluntary licensing and access programs.

DrugChatter Q&A for HARVONI

Harvoni approval date?
How effective is harvoni for hepatitis c genotype 1?